PG(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2S)-2,3-dihydroxypropoxy][(2R)-3-[(22-methyltetracosanoyl)oxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphinic acid

Formula: C51H91O13P (942.6197)
Chinese Name:
BioDeep ID: BioDeep_00000196011 ( View LC/MS Profile)
SMILES: [H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCC[C@@H](O)[C@H](O)\C=C/C=C\C=C\C=C\[C@@H](O)C\C=C/CC



Found 14 Sample Hits

m/z Adducts Species Organ Scanning Sample
942.6589 [M-H2O+NH4]+
PPM:16.9
Mus musculus Left upper arm MALDI (CHCA)
357_l_total ion count - Limb defect imaging - Monash University
Resolution: 50μm, 97x131

Description

Diseased

943.6254 [M+H]+
PPM:1.7
Mytilus edulis mantle MALDI (DHB)
20190216_MS38_Mytilus_mantle_350-1500_DHB_pos_A26_10um_275x210 - MTBLS2960
Resolution: 10μm, 275x210

Description

943.6358 [M+H]+
PPM:9.4
Mus musculus brain MALDI (DHB)
Brain01_Bregma-3-88b_centroid - MTBLS313
Resolution: 17μm, 265x320

Description

942.6372 [M-H2O+NH4]+
PPM:6.1
Mus musculus brain MALDI (DHB)
Brain01_Bregma1-42_02_centroid - MTBLS313
Resolution: 17μm, 434x258

Description

943.6407 [M+H]+
PPM:14.5
Mus musculus brain MALDI (DHB)
Brain01_Bregma1-42_02_centroid - MTBLS313
Resolution: 17μm, 434x258

Description

942.6362 [M-H2O+NH4]+
PPM:7.2
Mus musculus brain MALDI (DHB)
Brain01_Bregma1-42_01_centroid - MTBLS313
Resolution: 17μm, 447x118

Description

943.6398 [M+H]+
PPM:13.6
Mus musculus brain MALDI (DHB)
Brain01_Bregma1-42_01_centroid - MTBLS313
Resolution: 17μm, 447x118

Description

942.6188 [M]+
PPM:0.4
Mus musculus brain MALDI (DHB)
Brain02_Bregma1-42_03 - MTBLS313
Resolution: 17μm, 483x403

Description

942.6328 [M-H2O+NH4]+
PPM:10.8
Mus musculus brain MALDI (DHB)
Brain02_Bregma1-42_03 - MTBLS313
Resolution: 17μm, 483x403

Description

943.6363 [M+H]+
PPM:9.9
Mus musculus brain MALDI (DHB)
Brain02_Bregma1-42_03 - MTBLS313
Resolution: 17μm, 483x403

Description

942.6326 [M-H2O+NH4]+
PPM:11
Mus musculus brain MALDI (DHB)
Brain02_Bregma-3-88 - MTBLS313
Resolution: 17μm, 288x282

Description

943.622 [M+H]+
PPM:5.3
Mus musculus brain MALDI (DHB)
Brain02_Bregma-3-88 - MTBLS313
Resolution: 17μm, 288x282

Description

942.6188 [M]+
PPM:0.4
Mus musculus brain MALDI (DHB)
Brain02_Bregma-1-46 - MTBLS313
Resolution: 17μm, 294x399

Description

943.6221 [M+H]+
PPM:5.2
Mus musculus brain MALDI (DHB)
Brain02_Bregma-1-46 - MTBLS313
Resolution: 17μm, 294x399

Description


PG(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(a-25:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 22-methyltetracosanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).